RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation.
Recently, the rearrangement of RET proto-oncogene has been reported to be the most common genetic change in papillary thyroid carcinoma (PTC). However, its prevalence has been reported variably and its relation to clinical outcome has been controversial. The characteristic nuclear features of PTC usually render the diagnosis, but problem arises with equivocal cytologic features that are present focally. Although there remains some controversy, CK19 has been reported to be a useful ancillary tool for diagnosis of PTC. To evaluate the expression rate of RET/PTC rearrangement and CK19 in PTCs in a Korean population, we studied 115 papillary thyroid carcinomas in 3 mm-core tissue microarray based immunohistochemical analysis. The prevalence of Ret protein expression was 62.6% and the CK19 immunoreactivity was 80.9%. There was no statistically significant association between the Ret positivity and CK19 immunoreactivity, although the percent agreement of the two was relatively high. The clinicopathological variables did not correlate with the expression of Ret. In conclusion, the prevalence of Ret protein expression and its clinicopathological implications in a Korean population are not much different from those reported in previous studies. However, its detection via immunohistochemistry can be a useful diagnostic tool for diagnosing papillary thyroid carcinoma in conjunction with CK19.
Shin
Eunah
E
Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Chung
Woung Youn
WY
Yang
Woo Ick
WI
Park
Cheong Soo
CS
Hong
Soon Won
SW
D000231:Adenocarcinoma, Papillary / Q000378:metabolism*; D000328:Adult; D002277:Carcinoma / Q000473:pathology; D045744:Cell Line, Tumor; D003593:Cytoplasm / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000096:biosynthesis*; D007723:Korea; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D015513:Oncogene Proteins / Q000096:biosynthesis*; D000090063:Proto-Oncogene Mas; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases / Q000096:biosynthesis*; D013964:Thyroid Neoplasms / Q000378:metabolism* / Q000473:pathology
C000715470:MAS1 protein, human; D015513:Oncogene Proteins; D000090063:Proto-Oncogene Mas; D007633:Keratins; D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human; D020794:Receptor Protein-Tyrosine Kinases
Virchows Arch. 1997 Dec;431(6):407-13
9428928
Virchows Arch. 1997 Jul;431(1):1-9
9247627
Am J Pathol. 1998 Nov;153(5):1443-50
9811335
Clin Endocrinol (Oxf). 1998 Sep;49(3):317-23
9861322
J Surg Oncol. 1999 Jun;71(2):76-81; discussion 81-2
10389862
Clin Cancer Res. 1998 Feb;4(2):287-94
9516913
J Clin Endocrinol Metab. 1998 May;83(5):1629-32
9589668
Thyroid. 1998 Jun;8(6):485-9
9669285
Hum Pathol. 1999 Oct;30(10):1166-71
10534163
Thyroid. 1999 Dec;9(12):1237-43
10646664
Am J Pathol. 2001 Apr;158(4):1245-51
11290542
Br J Surg. 2001 Apr;88(4):557-63
11298625
Mod Pathol. 2001 Apr;14(4):338-42
11301350
Am J Clin Pathol. 2001 Nov;116(5):696-702
11710686
Eur J Endocrinol. 2001 Nov;145(5):599-604
11720878
Histopathology. 2002 Sep;41(3):236-43
12207785
Surg Today. 2004;34(6):485-92
15170542
Am J Clin Pathol. 1989 Nov;92(5):654-8
2479256
Cell. 1990 Feb 23;60(4):557-63
2406025
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1616-20
1542652
J Clin Invest. 1992 May;89(5):1517-22
1569189
Oncogene. 1992 Jul;7(7):1331-7
1620547
Jpn J Cancer Res. 1992 Jul;83(7):671-5
1381340
Cancer. 1994 Jan 1;73(1):176-80
8275421
Mod Pathol. 1994 Apr;7(3):295-300
7520169
Oncogene. 1995 Sep 21;11(6):1207-10
7566982
J Clin Endocrinol Metab. 1996 Sep;81(9):3360-5
8784097
Genes Chromosomes Cancer. 1996 May;16(1):1-14
9162191
J Clin Endocrinol Metab. 1997 Apr;82(4):1306-7
9100614
J Clin Endocrinol Metab. 1997 Jul;82(7):2322-8
9215314
J Pathol. 1998 May;185(1):71-8
9713362